'Hiv vaccine' presentation slideshows

Statistical Science Issues in Preventive HIV Vaccine Efficacy Trials: Part II

Statistical Science Issues in Preventive HIV Vaccine Efficacy Trials: Part II Outline Efficacy Trial Objectives Phase IIb vs Phase III Scientific questions Approaches to the questions HIV infection endpoint Post-infection endpoints Correlates of protective immunity

956 views • 51 slides

BIOE 301

BIOE 301. Lecture Ten. How do vaccines work? Stimulate immunity without causing disease How are vaccines made? Non-infectious vaccines Live, attenuated bacterial or viral vaccines Carrier Vaccines DNA Vaccines How are vaccines tested? Lab/Animal testing Phase I-III human testing

839 views • 47 slides

Major Sutchana Tabprasit Armed Forces Research Institute of Medical Sciences (AFRIMS),

Recent Trends in estimated HIV-1 Incidence among Royal Thai Army (RTA) conscripts from 2005-2009 in Thailand. Major Sutchana Tabprasit Armed Forces Research Institute of Medical Sciences (AFRIMS), Royal Thai Army (RTA), Bangkok, Thailand. Primary HIV-1 Infection. Acute infection

551 views • 45 slides

RV144: Clinical Development Plans

RV144: Clinical Development Plans. Nelson L. Michael, M.D., Ph.D Colonel, Medical Corps, U.S. Army Director US Military HIV Research Program (MHRP) Walter Reed Army Institute of Research. IAS 2012, Washington, DC USA

1.24k views • 38 slides

626 views • 32 slides

420 views • 28 slides

RETROVIRUS

RETROVIRUS. Bushra Rehman FA08-BBS-004. Table of contents. INTRODUCTION OF RETROVIRUS GENOME AND STRUCTURE OF RETROVIRUS HISTORY OF HIV TYPES OF HIV TRANSMISSION OF HIV GENOME AND STRUCTURE OF HIV REPLICATION OF HIV IMMUNE RESPONSE TO HIV THERAPY SIGNS AND SYMPTOMS OF HIV

821 views • 26 slides

HIV/AIDS VACCINE AWARENESS Vaccine 101 Jeremiah Brewer Health and Training Educator

448 views • 26 slides

HIV Science Update from Rome to Addis : Basic Science

HIV Science Update from Rome to Addis : Basic Science. Coumba Toure Kane Dakar University Senegal. Introduction. Basic science research ? valuable scientific information Questions still remain about:

221 views • 22 slides

2013

Informed Consent in HIV vaccine trials Clinton Rautenbach, Graham Lindegger & Catherine Slack HAVEG, Discipline of Psychology School of Applied Human Sciences, UKZN, PMB. 2013. http://www.saavi.org.za/haveg.htm. 1. Introduction to IC?.

362 views • 22 slides

Linking Clinical Cohorts and Basic/Clinical Science in Developing Countries

385 views • 20 slides

Strategies for Managing Innovation for Neglected Health Needs: Some experiences from India

Strategies for Managing Innovation for Neglected Health Needs: Some experiences from India. Dr K. Satyanarayana Sr Deputy Director-General & Chief, Intellectual Property Rights Unit Indian Council of Medical Research New Delhi 110029 India Kanikaram_s@yahoo.com. Scope of my talk.

485 views • 17 slides

Killing Kinetics of Simian Immunodeficiency Virus-Specific CD8+ T Cells: Implications for HIV Vaccine Strategies

Killing Kinetics of Simian Immunodeficiency Virus-Specific CD8+ T Cells: Implications for HIV Vaccine Strategies. Erik Rollman, Miranda Z. Smith, Andrew G. Brooks, Damian F.J. Purcell, Bartek Zuber, Ian A. Ramshaw, and Stephen J. Kent. Presented by Sarah Mohn and Mari Hammerquist. Goals.

297 views • 16 slides

HIV Vaccine Development: An Industry Perspective

HIV Vaccine Development: An Industry Perspective. Jim Tartaglia, PhD Vice-President R & D sanofi pasteur, Ltd. Toronto, Canada. XVI International AIDS Conference A World Without AIDS: The Long Road to Effective HIV Vaccines August 15, 2006.

390 views • 16 slides

ART Program of the HIV Vaccine Trials Network

ART Program of the HIV Vaccine Trials Network Margaret Wecker, PhD Associate Director, Scientific Operations and Business Development HVTN Organization HVTN functions under a cooperative agreement with the US National Institutes of Health

582 views • 13 slides

ART Program of the HIV Vaccine Trials Network

ART Program of the HIV Vaccine Trials Network. Margaret Wecker, PhD Associate Director, Scientific Operations and Business Development. HVTN Organization . HVTN functions under a cooperative agreement with the US National Institutes of Health

266 views • 13 slides

Carl W. Dieffenbach , Ph.D. Director Division of AIDS, NIAID July 2, 2013

HIV Vaccine and Future Strategies . Carl W. Dieffenbach , Ph.D. Director Division of AIDS, NIAID July 2, 2013. This session will review past HIV vaccine efforts, as well as novel viral vectors and advances in the design of vaccines to induce neutralizing antibodies.

226 views • 11 slides

HIV Vaccine Research & Development

260 views • 11 slides

INTERAGENCY & STRATEGIC OUTREACH OFFICE

INTERAGENCY & STRATEGIC OUTREACH OFFICE. A trusted partner for leading biomedical research and materiel innovation for global health. Presented to the USAMRMC Advanced Planning Briefing for Industry (APBI) and Small Business Conference By Mr. M. Steve Rountree Associate Director, USAMRMC

91 views • 9 slides

SCREENING FOR HIV RESPONSES USING OPTIMAL EPITOPES PREDICTED BY HLA-VIRAL SEQUENCE POLYMORPHISM ASSOCIATIONS.

Coat with INF- g capture Ab . Add peptide & cells. Add biotinylated detection Ab. Add streptavidin enzyme. Add TMB. SCREENING FOR HIV RESPONSES USING OPTIMAL EPITOPES PREDICTED BY HLA-VIRAL SEQUENCE POLYMORPHISM ASSOCIATIONS. . ACTG (n=555) + WA cohort (n=245). HLA-alleles (n=800) .

81 views • 1 slides